2/27
08:32 am
ntla
Intellia Therapeutics (NTLA) had its "buy" rating reaffirmed by Chardan Capital. They now have a $26.00 price target on the stock.
Low
Report
Intellia Therapeutics (NTLA) had its "buy" rating reaffirmed by Chardan Capital. They now have a $26.00 price target on the stock.
2/26
09:55 pm
ntla
Intellia Therapeutics, Inc. (NTLA) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
Intellia Therapeutics, Inc. (NTLA) Q4 2025 Earnings Call Transcript [Seeking Alpha]
2/26
03:03 pm
ntla
Intellia (NTLA) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Intellia (NTLA) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
2/26
08:13 am
ntla
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates [Yahoo! Finance]
Low
Report
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates [Yahoo! Finance]
2/26
07:38 am
ntla
Intellia Therapeutics GAAP EPS of -$0.83 beats by $0.12, revenue of $23.02M beats by $10.85M [Seeking Alpha]
Low
Report
Intellia Therapeutics GAAP EPS of -$0.83 beats by $0.12, revenue of $23.02M beats by $10.85M [Seeking Alpha]
2/26
07:30 am
ntla
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
Low
Report
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
2/24
08:00 am
ntla
Intellia Therapeutics to Participate in Upcoming Investor Conferences
Medium
Report
Intellia Therapeutics to Participate in Upcoming Investor Conferences
2/19
07:42 am
ntla
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates [Yahoo! Finance]
Medium
Report
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates [Yahoo! Finance]
2/19
07:30 am
ntla
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
Medium
Report
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
2/6
07:30 am
ntla
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/5
02:00 pm
ntla
Intellia Therapeutics: 2 Major Catalysts Will Determine Stock's Trajectory In 2026 [Seeking Alpha]
Low
Report
Intellia Therapeutics: 2 Major Catalysts Will Determine Stock's Trajectory In 2026 [Seeking Alpha]
2/2
09:40 am
ntla
Baird Updates Intellia Therapeutics, Inc. (NTLA)'s Financial Model Following Nex-Z Clinical Hold Removal [Yahoo! Finance]
Low
Report
Baird Updates Intellia Therapeutics, Inc. (NTLA)'s Financial Model Following Nex-Z Clinical Hold Removal [Yahoo! Finance]
1/28
05:49 pm
ntla
NTLA Stock Up More Than 6% as FDA Lifts ATTRv-PN Study Clinical Hold [Yahoo! Finance]
Low
Report
NTLA Stock Up More Than 6% as FDA Lifts ATTRv-PN Study Clinical Hold [Yahoo! Finance]
1/28
10:59 am
ntla
Intellia Therapeutics (NASDAQ:NTLA) was given a new $25.00 price target on by analysts at KeyCorp.
Low
Report
Intellia Therapeutics (NASDAQ:NTLA) was given a new $25.00 price target on by analysts at KeyCorp.
1/28
09:52 am
ntla
Intellia Therapeutics (NTLA) Surges 6.3%: Is This an Indication of Further Gains? [Yahoo! Finance]
Low
Report
Intellia Therapeutics (NTLA) Surges 6.3%: Is This an Indication of Further Gains? [Yahoo! Finance]
1/28
08:05 am
ntla
Cutting DNA, Cutting Edge: Companies Using CRISPR and Other Gene Editing Technologies to Rewrite the Future of Industry and Medicine
Medium
Report
Cutting DNA, Cutting Edge: Companies Using CRISPR and Other Gene Editing Technologies to Rewrite the Future of Industry and Medicine
1/28
07:19 am
ntla
Intellia Therapeutics (NASDAQ:NTLA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Intellia Therapeutics (NASDAQ:NTLA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
1/27
03:02 pm
ntla
Intellia Therapeutics (NASDAQ:NTLA) was given a new $7.00 price target on by analysts at Robert W. Baird.
Medium
Report
Intellia Therapeutics (NASDAQ:NTLA) was given a new $7.00 price target on by analysts at Robert W. Baird.
1/27
12:28 pm
ntla
FDA lifts hold on an Intellia CRISPR drug trial [Yahoo! Finance]
Low
Report
FDA lifts hold on an Intellia CRISPR drug trial [Yahoo! Finance]
1/27
08:33 am
ntla
US FDA lifts clinical hold on Intellia's nerve disease trial [Yahoo! Finance]
High
Report
US FDA lifts clinical hold on Intellia's nerve disease trial [Yahoo! Finance]
1/27
08:32 am
ntla
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN [Yahoo! Finance]
High
Report
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN [Yahoo! Finance]
1/27
08:00 am
ntla
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN
Low
Report
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN
1/24
05:08 am
ntla
Intellia Therapeutics (NASDAQ:NTLA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Intellia Therapeutics (NASDAQ:NTLA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/21
01:16 am
ntla
Intellia Therapeutics: Maintaining A Sell Rating As Platform Risks Escalate [Seeking Alpha]
Medium
Report
Intellia Therapeutics: Maintaining A Sell Rating As Platform Risks Escalate [Seeking Alpha]
1/20
12:26 am
ntla
Is Intellia Therapeutics (NTLA) Pricing Make Sense After Recent 35% Monthly Surge [Yahoo! Finance]
Low
Report
Is Intellia Therapeutics (NTLA) Pricing Make Sense After Recent 35% Monthly Surge [Yahoo! Finance]